Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.


Updates from The Motley Fool

Latest updates on Ophthotech from Fool.com.


Stock Performance

OPHT vs. S&P 500 | 2 Year Performance
View Interactive OPHT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Ophthotech.
Current Price: $54.12
Prev Close: $57.30
Open: $57.27
Bid: $53.61
Ask: $63.00
Day's Range: $53.44 - $57.72
52wk Range: $36.82 - $80.00
Volume: 831,104
Avg Vol 524,232
Market Cap: $1.89B
P/E (ttm): -14.15
EPS (ttm): -$4.05
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Ophthotech.
CAPS Rating 5 out of 5
 
48 Outperform
2 Underperform
CAPS All Stars
 
8 Outperform
1 Underperform

How do you think Ophthotech will perform against the market?



You pick for Ophthotech is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Ophthotech.

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.

  • Exchange: NASDAQ